Innovative Pharmacological Therapies in Osteoporosis Management: A Focus on Emerging Treatments

Abstract

Background: Osteoporosis, a prevalent condition among aging populations, significantly increases fracture risk due to reduced bone mineral density (BMD) and compromised bone architecture. Traditional pharmacological treatments like bisphosphonates and selective estrogen receptor modulators (SERMs) have shown efficacy, but emerging therapies are offering new hope for enhanced outcomes.
Methods: This review examines the efficacy, safety, and mechanisms of action of novel osteoporosis treatments, including sclerostin inhibitors, parathyroid hormone analogs, and dual-acting bone agents, based on recent clinical trials and meta-analyses.
Results: Emerging therapies demonstrated superior BMD improvements and fracture risk reduction compared to traditional treatments, with notable progress in anabolic and dual-action agents.
Conclusion: Innovative pharmacological treatments are redefining osteoporosis management. These therapies, in combination with lifestyle interventions, hold great promise for improving patient outcomes and quality of life.